ArticleAIDS research and treatment2012
TB and HIV Therapeutics: Pharmacology Research Priorities.
Article in AIDS research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.Antimicrobial agents and chemotherapy · 2014Trial
- Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-CobicistatAntimicrobial agents and chemotherapy · 2017Article
- Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?The Korean journal of internal medicine · 2016Review
- How to manage children who have come into contact with patients affected by tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2015Review
- Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe.HIV medicine · 2015Article
- The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.Antimicrobial agents and chemotherapy · 2015Article
- Pharmacologic considerations in use and development of antituberculosis drugs.Cold Spring Harbor perspectives in medicine · 2014Review
- Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Antimicrobial agents and chemotherapy · 2014Article
- Prevalence and patterns of multimorbidity among tuberculosis patients in Brazil: a cross-sectional study.International journal for equity in health · 2013Article
- Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care. To ensure that combinations of anti-tuberculosis drugs and antiretrovirals are safe and are tested at doses most likely to be effective, selected pharmacokinetic studies based on knowledge of their metabolic pathways and their capacity to induce or inhibit metabolizing enzymes of companion drugs must be conducted. Drug interaction studies should be followed up by evaluations in larger populations to evaluate safety and pharmacodynamics more fully. Involving patients with HIV in trials of TB drugs early in development enhances the knowledge gained from the trials and will ensure that promising new tuberculosis treatments are available to patients with HIV as early as possible. In this review, we summarize current and planned pharmacokinetic and drug interaction studies involving investigational and licensed tuberculosis drugs and antiretrovirals and suggest priorities for tuberculosis-HIV pharmacokinetic, pharmacodynamic, and drug-drug interaction studies for the future. Priority studies for children and pregnant women with HIV and tuberculosis co-infection are briefly discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.